Cargando…
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
Ovarian cancer is the leading cause of gynecological cancer death. Improved understanding of the biologic pathways and introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) during the last decade have changed the treatment landscape. This has improved outcomes, but unfortunately half the w...
Autores principales: | Garg, Vikas, Oza, Amit M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581945/ https://www.ncbi.nlm.nih.gov/pubmed/37737434 http://dx.doi.org/10.1007/s40265-023-01934-0 |
Ejemplares similares
-
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer
por: Palleschi, Michela, et al.
Publicado: (2021) -
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020) -
New treatment option for ovarian cancer: PARP inhibitors
por: Meehan, Robert S., et al.
Publicado: (2016) -
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018) -
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
por: Jiang, Xuan, et al.
Publicado: (2019)